For the first time in more than 10 years, idiopathic pulmonary fibrosis (IPF) care teams and patients will have a new treatment option following the Oct. 7 approval of Jascayd (nerandomilast) by the U.S. Food and Drug Administration (FDA). When I was diagnosed with IPF in January 2017, the only anti-fibrotic medications available to treat […] The post Jascayd is approved! So when can we start taking the IPF treatment? appeared first on Pulmonary Fibrosis News.
